🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in China / NCT06131489
Starting soon Observational

Segmental Resection Combined With DEP Regimen for EBV-HLH Patients With Intestinal Involvement

NCT06131489 · tracked via the Priya Life Science China tracker
Sponsor
Beijing Friendship Hospital
Phase
Observational
Started
2023-12-01
Last updated
2023-11-14

Condition(s) studied

Hemophagocytic LymphohistiocytosisEpstein-Barr VirusBowel Resection

Investigational drug(s) / intervention(s)

Segmental bowel resection combined with the DEP regimen

Segmental bowel resection combined with the DEP regimen: Segmental bowel resection combined with liposomal doxorubicin, etoposide, and methylprednisolone administered in 2 week cycles for 2 cycles

Study summary

EBV-HLH is a rare disease with high mortality, especially for those with intestinal involvement. In order to reduce disease burden and improve survival of these patients, we conduct a prospective observational study to explore the efficacy and safety of segmental resection combined with the DEP regimen.

Eligibility

Sex
ALL
Min age
18 Years
Max age
Healthy volunteers
No
Inclusion Criteria: * Met HLH-2004 diagnostic criteria; * EBV-DNA in the peripheral blood \> 1000 copies/ml or EBV-encoded small RNA (EBER) detected in tissues; * Imaging revealed severe intestinal lesions and biopsy confirmed EBV-encoded small RNA (EBER) in the tissues; * Age \>18 years old, gender is not limited; * Estimated survival time \> 1 month; * Informed consent obtained. Exclusion Criteria: * Active infections (viral, bacterial, fungal or parasitic); * Diagosed with malignant tumos within 5 years; * Uncontrolled symptoms or other diseases including, but not limited to, unstable angina pectoris, arrhythmia, respiratory failure, severe hepatic or renal insufficiency, severe coagulation dysfunction, mental illness, or other conditions deemed by the attending physician to be contraindications to surgery; * Heart function above grade II (NYHA); * Severe myocardial injury:TNT、TNI、CK-MB \> 3 ULN; * Accumulated dose of doxorubicin above 400mg/m2 、epirubicin above 750mg/m2、pirarubicin above 800mg/m2 or the patients treated with anthracycline induced cardiovascular disease; * Pregnancy or lactating Women; * Allergic to pegylated liposomal doxorubicin and etoposide; * HIV antibody positivity; * Acute or chronic active hepatitis B (HBsAg positivity, HBV DNA negative acceptable), acute or chronic active hepatitis C (HCV antibody negatively acceptable; HCV antibody positivity, HCV RNA negative acceptable); * Participate in other clinical research at the same time; * The researchers considered that patients are not suitable for the study.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Zhao Wang Beijing Beijing Municipality

More Beijing Friendship Hospital trials in China

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06131489 on ClinicalTrials.gov ↗ ← All trials in China